|
Shanghai Hile Bio-Technology Co., Ltd. (603718.SS) Valoración de DCF |
Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
Predeterminadas Para Un Uso Rápido Y Eficiente
Compatible con MAC / PC, completamente desbloqueado
No Se Necesita Experiencia; Fáciles De Seguir
Shanghai Hile Bio-Technology Co., Ltd. (603718.SS) Bundle
Ya sea que sea un inversor o analista, esta calculadora DCF (603718SS) es su herramienta esencial para una valoración precisa. Cargados con datos reales de Shanghai Hile Bio-Technology Co., Ltd., puede ajustar los pronósticos y observar los efectos en tiempo real.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 259.1 | 347.3 | 300.0 | 240.7 | 271.0 | 280.0 | 289.3 | 298.9 | 308.7 | 319.0 |
| Revenue Growth, % | 0 | 34.02 | -13.62 | -19.76 | 12.59 | 3.31 | 3.31 | 3.31 | 3.31 | 3.31 |
| EBITDA | 59.7 | 120.5 | 183.3 | 101.1 | 251.0 | 141.9 | 146.6 | 151.5 | 156.5 | 161.7 |
| EBITDA, % | 23.05 | 34.69 | 61.1 | 42.01 | 92.62 | 50.69 | 50.69 | 50.69 | 50.69 | 50.69 |
| Depreciation | 67.7 | 61.5 | 49.6 | 40.9 | 37.4 | 51.0 | 52.7 | 54.5 | 56.3 | 58.1 |
| Depreciation, % | 26.12 | 17.7 | 16.55 | 16.98 | 13.81 | 18.23 | 18.23 | 18.23 | 18.23 | 18.23 |
| EBIT | -8.0 | 59.0 | 133.6 | 60.3 | 213.6 | 90.9 | 93.9 | 97.0 | 100.2 | 103.5 |
| EBIT, % | -3.07 | 16.99 | 44.55 | 25.03 | 78.81 | 32.46 | 32.46 | 32.46 | 32.46 | 32.46 |
| Total Cash | 520.7 | 538.6 | 392.7 | 353.2 | 517.1 | 280.0 | 289.3 | 298.9 | 308.7 | 319.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 59.9 | 121.4 | 97.4 | 89.9 | 111.9 | 94.7 | 97.9 | 101.1 | 104.5 | 107.9 |
| Account Receivables, % | 23.12 | 34.95 | 32.47 | 37.33 | 41.28 | 33.83 | 33.83 | 33.83 | 33.83 | 33.83 |
| Inventories | 115.9 | 142.6 | 144.9 | 102.8 | 55.0 | 110.4 | 114.0 | 117.8 | 121.7 | 125.7 |
| Inventories, % | 44.75 | 41.07 | 48.3 | 42.71 | 20.3 | 39.42 | 39.42 | 39.42 | 39.42 | 39.42 |
| Accounts Payable | 32.7 | 39.4 | 43.2 | 30.1 | 8.8 | 30.3 | 31.3 | 32.4 | 33.4 | 34.5 |
| Accounts Payable, % | 12.63 | 11.35 | 14.4 | 12.52 | 3.25 | 10.83 | 10.83 | 10.83 | 10.83 | 10.83 |
| Capital Expenditure | -34.1 | -37.8 | -19.8 | -7.8 | -8.4 | -20.7 | -21.4 | -22.1 | -22.8 | -23.6 |
| Capital Expenditure, % | -13.17 | -10.88 | -6.62 | -3.25 | -3.1 | -7.4 | -7.4 | -7.4 | -7.4 | -7.4 |
| Tax Rate, % | 17.75 | 17.75 | 17.75 | 17.75 | 17.75 | 17.75 | 17.75 | 17.75 | 17.75 | 17.75 |
| EBITAT | -11.0 | 55.6 | 123.8 | 67.6 | 175.7 | 85.3 | 88.1 | 91.0 | 94.0 | 97.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -120.5 | -2.1 | 179.1 | 137.2 | 209.2 | 98.9 | 113.7 | 117.4 | 121.3 | 125.3 |
| WACC, % | 4.73 | 4.73 | 4.73 | 4.73 | 4.71 | 4.73 | 4.73 | 4.73 | 4.73 | 4.73 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 500.6 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 130 | |||||||||
| Terminal Value | 17,928 | |||||||||
| Present Terminal Value | 14,231 | |||||||||
| Enterprise Value | 14,732 | |||||||||
| Net Debt | -309 | |||||||||
| Equity Value | 15,041 | |||||||||
| Diluted Shares Outstanding, MM | 658 | |||||||||
| Equity Value Per Share | 22.85 |
What You Will Receive
- Customizable Excel Template: A fully adaptable Excel-based DCF Calculator featuring pre-populated financials for Shanghai Hile Bio-Technology Co., Ltd. (603718SS).
- Real Market Data: Access to historical figures and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Adjust key assumptions such as revenue growth, EBITDA percentage, and WACC to fit your analysis.
- Instant Calculations: Quickly observe how your inputs influence the valuation of Shanghai Hile Bio-Technology Co., Ltd. (603718SS).
- Professional-Grade Tool: Designed for investors, CFOs, consultants, and financial analysts looking to enhance their analysis.
- User-Friendly Interface: Organized for simplicity and ease of navigation, complete with step-by-step guidance.
Key Features
- 🔍 Real-Life Shanghai Hile Financials: Pre-filled historical and projected data for Shanghai Hile Bio-Technology Co., Ltd. (603718SS).
- ✏️ Fully Customizable Inputs: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas assess Shanghai Hile's intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: View Shanghai Hile's valuation immediately upon making adjustments.
- Scenario Analysis: Evaluate and compare results for different financial assumptions side-by-side.
How It Works
- 1. Access the Template: Download and open the Excel file containing Shanghai Hile Bio-Technology Co., Ltd.'s (603718SS) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures tailored to your analysis.
- 3. See Instant Results: The DCF model automatically computes the intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Evaluate various forecasts to investigate different valuation outcomes for (603718SS).
- 5. Present with Assurance: Deliver professional valuation insights to inform your decision-making process regarding (603718SS).
Why Select This Calculator?
- User-Friendly: Crafted for both novices and seasoned users.
- Customizable Inputs: Modify parameters effortlessly to suit your analysis.
- Real-Time Feedback: Observe immediate changes in Shanghai Hile Bio-Technology Co., Ltd.'s (603718SS) valuation as you adjust parameters.
- Pre-Configured: Comes preloaded with Shanghai Hile's actual financial data for swift evaluation.
- Relied Upon by Experts: A go-to tool for investors and analysts making well-informed choices.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for portfolio assessments of Shanghai Hile Bio-Technology Co., Ltd. (603718SS).
- Corporate Finance Teams: Evaluate valuation scenarios to inform internal strategic decisions regarding Shanghai Hile Bio-Technology Co., Ltd. (603718SS).
- Consultants and Advisors: Deliver precise valuation insights related to Shanghai Hile Bio-Technology Co., Ltd. (603718SS) for client engagements.
- Students and Educators: Utilize real-time data to enhance financial modeling practice and education focused on Shanghai Hile Bio-Technology Co., Ltd. (603718SS).
- Biotech Enthusiasts: Gain a deeper understanding of market valuation methods for biotech companies like Shanghai Hile Bio-Technology Co., Ltd. (603718SS).
What the Template Includes
- Comprehensive DCF Model: An editable template featuring detailed valuation computations.
- Real-World Data: Historical and projected financials for Shanghai Hile Bio-Technology Co., Ltd. (603718SS) preloaded for analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for in-depth insights.
- Key Ratios: Integrated analysis covering profitability, efficiency, and leverage.
- Dashboard with Visual Outputs: Charts and tables providing clear, actionable insights.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.